Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts
Executive Summary
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
You may also be interested in...
Ipsen Hungry For More Deals After Swallowing Epizyme
Ipsen CEO David Loew recently told Scrip that a return to more rational valuations for biotechs should led to more deals. The Epizyme acquisition could be the first of many by the French group this year.
Genmab Confident It Has Edge Over Roche In Bispecific Battle
Genmab may only recently have launched its first commercial operations with Tivdak, but is stepping up to co-market epcoritamab with AbbVie against the might of Roche in the new CD20xCD3 field.
ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics
Roche looks set to gain first and second place in the race to bring CD3xCD20s to market – but Genmab and AbbVie have a strong challenger.